Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Date:12/9/2008

3% 4% 3% Anxiety 0% 0% 2% Headache 9% 4% 2% Dry mouth 2% 2% 1% Nausea 2% 0% 1% Stomach discomfort 2% 3% 1% Diarrhea 3% 1% 0% Skin rash 2% 1% 0%

"The positive results from this second Phase 3 study, corroborating our first Phase 3 findings, show that AZ-004 has the potential to be a viable product to acutely treat agitation," said Thomas B. King, Alexza President and CEO. "We are very encouraged with the pace at which we have developed into a pre-NDA stage company. In addition to our clinical successes, we are aggressively escalating many commercialization activities, including our commercial manufacturing scale-up, quality systems, regulatory affairs and strategic marketing initiatives, as we continue to track toward our planned AZ-004 NDA submission in early 2010."

Conference Call Information

Alexza will host a conference call later today, Tuesday, December 9, 2008 at 5:00 p.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call and replay are open to all interested parties.

To access the conference call via the Internet, go to http://www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
2. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... YORK , May 28, 2015 /PRNewswire/ ... developing new drugs and tests, and this ... the instruments that can assist them. This according ... publisher. Kalorama Information said instruments such as mass ... assist in the identification of drug targets ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3
... -- The,first of two stages of the ... Kamada's Alpha-1 Antitrypsin (AAT) liquid drug,candidate for ... the treatment of patients suffering from AAT,deficiency. ... profiles,and patient tolerability, leading the way to ...
... WIRE)--Jun 1, 2007 - Arrowhead Research,Corporation (Nasdaq:ARWR) ... been published in the 2007 American Society ... The data are from,an ongoing Phase I ... and pharmacokinetics of its lead anti-cancer drug,candidate, ...
Cached Medicine Technology:PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 2PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 3Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 2Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 The science ... in Los Angeles thanks to the efforts of internationally ... Mohebi has combined ARTAS hair restoration and ... hair restoration procedures available anywhere. , A Follicular ... and individually harvesting hair follicle grafts from the donor ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 John A. ... to Cincinnati , The Department of Veterans Affairs (VA) ... Gennaro as the new director of the Cincinnati VA ... care to more than 43,000 unique Veterans annually and ... over 2,000 staff, CVAMC is a two-division campus located ...
(Date:5/29/2015)... The science of Follicular Unit Extraction ... and more efficient methods of FUE hair transplantation have increased ... of the most cutting edge hair transplant methods being used ... technique of extracting hair from the beard to the scalp. ... to correct male pattern baldness. Beard hair has a ...
(Date:5/29/2015)... On May 21, 2015, Elle Magazine in article titled ... Botox ?” reported on the four most commonly searched beauty ... to determine these results and then sought expert help to ... example, is how to keep neck skin tight . ... the appropriate age to start receiving Botox injections . ...
(Date:5/29/2015)... To compile the list, the Becker's Hospital ... several awards for clinical and general excellence. The team ... to them in terms of overall excellence, and those ... 50 Great Health Systems to Know 2015 list includes ... Fla.) , Advocate Health Care (Downers Grove, Ill.) , ...
Breaking Medicine News(10 mins):Health News:Los Angeles and Beverly Hills Hair Transplant Doctor Now Combines Robotic Hair Restoration (ARTAS) and Manual FUE Transplants for Maximum Hair Coverage 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 3
... improves patient satisfaction scores, ATLANTA, Jan. ... effectively,measure individual performance and improve patient satisfaction ... patient,satisfaction benchmarks established through Press Ganey with ... score by 2 points within 24,months. In ...
... Jan. 25 Super Bowl Sunday,s almost here-and,what better ... healthy,and losing some weight. Right? As more than 90 ... biggest event of the year, we,plan parties predicting the ... With those big-guy pro,s gearing up for Super ...
... in Belgium have significantly advanced the discovery of a ... insulin-producing beta cells. If the finding made in mice ... an obvious target for therapeutic regeneration of beta cells ... issue of the research journal Cell, a publication of ...
... LOS ANGELES, Jan. 25 An unprecedented move,by residential ... came to the table to settle two class action ... 21, 2007 in Orange,County Superior Court, and one in ... Multnomah County Circuit Court and,should receive final approval in ...
... ALEXANDRIA, Va., Jan. 25 - In a speech,earlier ... revealed the,company was in the initial stages of ... RPh, executive vice president and CEO,of the National ... "The PBM industry badly needs to be reformed. ...
... Patients who got calls from those who had ... , , FRIDAY, Jan. 25 (HealthDay News) -- Patients who ... to undergo the screening for colorectal cancer, say University ... that people who received telephone mentoring from a trained ...
Cached Medicine News:Health News:Emory Healthcare Uses SciHealth to Improve Patient Satisfaction 2Health News:Super Bowl and SuperFoods: Play Smart 2Health News:Elusive pancreatic progenitor cells found in mice 2Health News:Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit 2Health News:Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit 3Health News:NCPA Statement on Wal-Mart's Entry Into the Pharmacy Benefit Market 2Health News:Colonoscopy 'Coaches' Play Lifesaving Role 2
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Medicine Products: